Center Laboratories, Inc.

As of June 30, 2026, Center Laboratories, Inc. carries a market capitalization of 28.77B, placing it among publicly traded companies globally. Its enterprise value stands at 29.02B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Center Laboratories, Inc. has 791.02M shares outstanding.

As of June 30, 2026, Center Laboratories, Inc. trades at a trailing price-to-earnings ratio of 28.17. The price-to-sales ratio is 17.33, and the price-to-book ratio stands at 1.68.

As of June 30, 2026, Center Laboratories, Inc. trades at an EV/EBITDA multiple of 123.30 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 17.52 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 522.10 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Center Laboratories, Inc. trades at an EV/FCF ratio of 122.56, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 29.02B versus a market cap of 28.77B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Center Laboratories, Inc. maintains a current ratio of 1.85, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 23.91, indicating elevated leverage, while an interest coverage ratio of 1.32 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Center Laboratories, Inc. posted a return on equity (ROE) of 6.00, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 0.16 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.28, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.18, useful for judging operating efficiency across full business cycles. The company generates approximately 8.58M in revenue per employee across its workforce of 193.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.03 indicates how many times Center Laboratories, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Center Laboratories, Inc. recorded 613.55M in income tax expense. That works out to an effective tax rate of 37.58, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.63B, leaving 1.02B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Center Laboratories, Inc.'s stock has declined approximately 9.22% over the past 52 weeks. The 50-day moving average sits at 31.29, while the 200-day moving average is 36.39.

Over the twelve months ended June 30, 2026, Center Laboratories, Inc. generated 1.66B in revenue and converted that into 1.02B in net income, yielding earnings per share of 1.20. EBITDA reached 235.38M, while operating income came in at 55.36M.

As of June 30, 2026, Center Laboratories, Inc. holds 3.85B in cash and equivalents against 4.10B in total debt, resulting in a net debt position of 740.04M. Total book value stands at 17.16B, with working capital of 2.03B providing operational flexibility.

Center Laboratories, Inc. produced 283.16M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -157.78M in capital expenditures, free cash flow totaled 125.38M - equivalent to 0.16 per share.

Over the twelve months ended June 30, 2026, Center Laboratories, Inc. posted a gross margin of 43.28, reflecting its pricing power and cost economics. The operating margin of 3.34 and net profit margin of 61.51 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 0.41, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 5.39, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Center Laboratories, Inc. shareholders.

Center Laboratories, Inc.'s most recent stock split took place on August 17, 2026 with a 1000:1049 split ratio.

As of June 30, 2026, Center Laboratories, Inc. has an Altman Z-Score of 2.31, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.